Kerendia (finerenone) is a prescription medication with two FDA-approved uses: protecting kidney function in adults with chronic kidney disease linked to type 2 diabetes, and reducing heart failure events in adults whose hearts still pump relatively normally. It belongs to a newer class of drugs that block a hormone receptor involved in inflammation and scarring of the heart and kidneys, and it works differently from older drugs in the same family.
Chronic Kidney Disease With Type 2 Diabetes
Kerendia’s first and most established use is slowing kidney damage in adults who have both chronic kidney disease (CKD) and type 2 diabetes. In this population, the drug reduces the risk of kidney function declining to the point of needing dialysis or a transplant. It also lowers the chance of cardiovascular death, heart attack, and hospitalization for heart failure, which are common complications in people with diabetic kidney disease.
Two large clinical trials, known as FIDELIO-DKD and FIGARO-DKD, tested Kerendia against a placebo in over 13,000 patients with diabetic kidney disease. In a pooled analysis published in the European Heart Journal, patients taking Kerendia had a 23% lower risk of a serious kidney event (kidney failure, major sustained decline in kidney filtration, or kidney-related death) compared to placebo. The cardiovascular benefits were consistent across both trials, with roughly a 13 to 14% reduction in a combined measure of heart attack, stroke, heart failure hospitalization, and cardiovascular death.
Heart Failure With Preserved Pumping Ability
In 2025, the FDA expanded Kerendia’s approval to include heart failure in adults whose heart still ejects at least 40% of its blood volume with each beat. This condition, sometimes called heart failure with preserved or mildly reduced ejection fraction, is notoriously difficult to treat and has fewer medication options than other forms of heart failure. In this setting, Kerendia is used to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits.
How Kerendia Works
Your body produces a hormone called aldosterone that regulates blood pressure and fluid balance. When aldosterone binds to mineralocorticoid receptors in the heart and kidneys, it can trigger inflammation, scarring (fibrosis), and tissue enlargement, especially in people with diabetes or heart failure. Over time, this damage stiffens the heart and destroys the kidney’s filtering units.
Kerendia blocks those mineralocorticoid receptors, shutting down the signals that drive inflammation and scarring. Older drugs like spironolactone and eplerenone do something similar, but they have a steroid-based structure that causes them to interact with other hormone receptors. That’s why spironolactone can cause breast tissue growth in men, menstrual irregularities, and sexual side effects. Kerendia’s non-steroidal structure gives it a much tighter fit on the mineralocorticoid receptor without activating progesterone or androgen receptors, so those hormonal side effects don’t occur.
Another key difference is tissue distribution. Older drugs concentrate more heavily in the kidneys, while Kerendia distributes equally between the heart and kidneys. In animal studies, Kerendia reversed heart enlargement and reduced kidney scarring even at doses too low to affect blood pressure, suggesting its benefits come from directly blocking organ damage rather than just lowering blood pressure.
Dosing Based on Kidney Function
Kerendia is taken as a single daily tablet, and the starting dose depends on how well your kidneys are currently filtering. Before prescribing it, your doctor will check your kidney filtration rate (eGFR) and blood potassium level. If your potassium is above 5.0 mEq/L, you cannot start the medication until it comes down.
- eGFR 60 or higher: starting dose is 20 mg once daily
- eGFR 25 to 59: starting dose is 10 mg once daily
- eGFR below 25: not recommended
Your potassium will be rechecked about four weeks after starting and periodically throughout treatment. Based on those results, your doctor may increase, maintain, or temporarily pause the dose.
High Potassium: The Main Side Effect
Because Kerendia blocks aldosterone’s action in the kidneys, it reduces how much potassium your body excretes. This means potassium can build up in your blood, a condition called hyperkalemia. In the FIDELIO-DKD trial, about 18% of patients on Kerendia developed elevated potassium levels, compared to 9% on placebo. Most cases were manageable with dose adjustments. About 2.3% of patients had to stop the drug entirely due to high potassium, and 1.4% required hospitalization for it.
This is why regular blood work matters. If you’re taking other medications that raise potassium, such as ACE inhibitors, ARBs, or potassium-sparing diuretics, the monitoring schedule may be more frequent. You should also avoid potassium supplements and salt substitutes containing potassium unless your doctor specifically approves them.
Drug Interactions to Know About
Kerendia is broken down in your liver by a specific enzyme system (CYP3A4), and anything that strongly blocks this enzyme can cause dangerously high levels of the drug in your blood. Strong CYP3A4 inhibitors are contraindicated, meaning you cannot take them together with Kerendia. Common examples include certain antifungal medications and some HIV treatments.
Grapefruit and grapefruit juice also inhibit this enzyme and should be avoided while on Kerendia. On the flip side, drugs that speed up CYP3A4 activity (strong or moderate inducers like certain seizure medications and the herbal supplement St. John’s wort) can make Kerendia less effective and should also be avoided.
People with adrenal insufficiency cannot take Kerendia, since their bodies already struggle to produce adequate aldosterone and other adrenal hormones. If you have moderate liver impairment, your doctor may monitor your potassium more closely, as the drug can linger longer in your system.
What Makes It Different From Older Options
Spironolactone has been available since the 1960s, and eplerenone since 2002. Both are effective at blocking mineralocorticoid receptors, but neither was specifically proven in large trials to protect kidneys in diabetic kidney disease the way Kerendia has been. Spironolactone’s hormonal side effects also limit its use, particularly in men. Eplerenone is more selective than spironolactone but still less selective than Kerendia, and it binds to the mineralocorticoid receptor with lower affinity.
Kerendia also has a short half-life and produces no active metabolites, meaning it clears your system relatively quickly and doesn’t leave behind breakdown products that continue to act on the body. For patients already taking diabetes medications, blood pressure drugs, and possibly SGLT2 inhibitors, Kerendia adds a distinct layer of protection by targeting the inflammation and fibrosis pathways that other treatments don’t directly address.